287 related articles for article (PubMed ID: 15561866)
1. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
[TBL] [Abstract][Full Text] [Related]
2. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
3. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Shubar HM; Lachenmaier S; Heimesaat MM; Lohman U; Mauludin R; Mueller RH; Fitzner R; Borner K; Liesenfeld O
J Drug Target; 2011 Feb; 19(2):114-24. PubMed ID: 20367080
[TBL] [Abstract][Full Text] [Related]
4. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
5. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.
Katlama C; Mouthon B; Gourdon D; Lapierre D; Rousseau F
AIDS; 1996 Sep; 10(10):1107-12. PubMed ID: 8874627
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
Chirgwin K; Hafner R; Leport C; Remington J; Andersen J; Bosler EM; Roque C; Rajicic N; McAuliffe V; Morlat P; Jayaweera DT; Vilde JL; Luft BJ
Clin Infect Dis; 2002 May; 34(9):1243-50. PubMed ID: 11941551
[TBL] [Abstract][Full Text] [Related]
7. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
8. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients.
Kongsaengdao S; Samintarapanya K; Oranratnachai K; Prapakarn W; Apichartpiyakul C
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(1):11-6. PubMed ID: 17517949
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone].
Guelar A; Miró JM; Mallolas J; Zamora L; Cardenal C; Gatell JM; Soriano E
Enferm Infecc Microbiol Clin; 1994 Mar; 12(3):137-40. PubMed ID: 8011719
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
12. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
13. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Podzamczer D; Miró JM; Ferrer E; Gatell JM; Ramón JM; Ribera E; Sirera G; Cruceta A; Knobel H; Domingo P; Polo R; Leyes M; Cosin J; Fariñas MC; Arrizabalaga J; Martínez-Lacasa J; Gudiol F
Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):89-95. PubMed ID: 10746493
[TBL] [Abstract][Full Text] [Related]
14. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.
Torres RA; Weinberg W; Stansell J; Leoung G; Kovacs J; Rogers M; Scott J
Clin Infect Dis; 1997 Mar; 24(3):422-9. PubMed ID: 9114194
[TBL] [Abstract][Full Text] [Related]
15. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.
Shubar HM; Dunay IR; Lachenmaier S; Dathe M; Bushrab FN; Mauludin R; Müller RH; Fitzner R; Borner K; Liesenfeld O
J Drug Target; 2009 May; 17(4):257-67. PubMed ID: 19255896
[TBL] [Abstract][Full Text] [Related]
16. Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Sina S; Mohammad JM; Reza S; Anita M; Soudabeh E; Hadi M
Eur J Med Res; 2021 Jun; 26(1):65. PubMed ID: 34193287
[TBL] [Abstract][Full Text] [Related]
17. A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
de Diego JA; Penin P; Arribas JR; Vázquez E; Vázquez JJ
Folia Microbiol (Praha); 1996; 41(6):513-6. PubMed ID: 9131805
[TBL] [Abstract][Full Text] [Related]
18. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.
Katlama C; De Wit S; O'Doherty E; Van Glabeke M; Clumeck N
Clin Infect Dis; 1996 Feb; 22(2):268-75. PubMed ID: 8838183
[TBL] [Abstract][Full Text] [Related]
19. Cerebral toxoplasmosis in childhood and adult HIV infection treated with 1-4 hydroxynaphthoquinone and rapid desensitization with pyrimethamine.
Bouboulis DA; Rubinstein A; Shliozberg J; Madden J; Frieri M
Ann Allergy Asthma Immunol; 1995 Jun; 74(6):491-4. PubMed ID: 7788516
[TBL] [Abstract][Full Text] [Related]
20. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease.
Gormley PD; Pavesio CE; Minnasian D; Lightman S
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1171-5. PubMed ID: 9620076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
